Correlation Between Lixte Biotechnology and TechPrecision Common

Can any of the company-specific risk be diversified away by investing in both Lixte Biotechnology and TechPrecision Common at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lixte Biotechnology and TechPrecision Common into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Lixte Biotechnology Holdings and TechPrecision Common, you can compare the effects of market volatilities on Lixte Biotechnology and TechPrecision Common and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lixte Biotechnology with a short position of TechPrecision Common. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lixte Biotechnology and TechPrecision Common.

Diversification Opportunities for Lixte Biotechnology and TechPrecision Common

0.47

Correlation Coefficient

Lixte Biotechnology  TechPrecision Common

Very weak diversification

The 3 months correlation between Lixte and TechPrecision is 0.47. Overlapping area represents the amount of risk that can be diversified away by holding Lixte Biotechnology Holdings and TechPrecision Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on TechPrecision Common and Lixte Biotechnology is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lixte Biotechnology Holdings are associated (or correlated) with TechPrecision Common. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of TechPrecision Common has no effect on the direction of Lixte Biotechnology i.e., Lixte Biotechnology and TechPrecision Common go up and down completely randomly.

Pair Corralation between Lixte Biotechnology and TechPrecision Common

Given the investment horizon of 90 days Lixte Biotechnology Holdings is expected to generate 3.01 times more return on investment than TechPrecision Common. However, Lixte Biotechnology is 3.01 times more volatile than TechPrecision Common. It trades about 0.19 of its potential returns per unit of risk. TechPrecision Common is currently generating about 0.16 per unit of risk. If you would invest  149.00  in Lixte Biotechnology Holdings on May 14, 2025 and sell it today you would earn a total of  349.00  from holding Lixte Biotechnology Holdings or generate 234.23% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Weak
Accuracy	98.39%
Values	Daily Returns

Lixte Biotechnology Holdings  vs.  TechPrecision Common

Lixte Biotechnology

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Lixte Biotechnology Holdings are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, Lixte Biotechnology unveiled solid returns over the last few months and may actually be approaching a breakup point.

TechPrecision Common

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in TechPrecision Common are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively fragile fundamental indicators, TechPrecision Common unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Lixte Biotechnology and TechPrecision Common

The main advantage of trading using opposite Lixte Biotechnology and TechPrecision Common positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lixte Biotechnology position performs unexpectedly, TechPrecision Common can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TechPrecision Common will offset losses from the drop in TechPrecision Common's long position.

The idea behind Lixte Biotechnology Holdings and TechPrecision Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.